Thursday, June 27, 2024 6:40:04 AM
Happy Trading
Recent VIGL News
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/19/2024 09:20:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/17/2024 11:16:00 AM
- Vigil Neuroscience Announces FDA Has Removed Partial Clinical Hold on VG-3927 • GlobeNewswire Inc. • 09/17/2024 11:00:00 AM
- Vigil Neuroscience to Present at Cantor Global Healthcare Conference • GlobeNewswire Inc. • 09/16/2024 08:05:00 PM
- Vigil Neuroscience to Present at Upcoming September Investor Conferences • GlobeNewswire Inc. • 08/29/2024 11:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2024 11:30:20 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2024 11:16:04 AM
- Vigil Neuroscience Reports Second Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/13/2024 11:00:00 AM
- Form SC 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 08/12/2024 09:02:26 PM
- Vigil Neuroscience Highlights Publication on ALSP Genetic Mutation Prevalence in Neurology Genetics • GlobeNewswire Inc. • 08/01/2024 08:05:00 PM
- Vigil Presents Data on its Small Molecule TREM2 Agonist Program at 2024 Alzheimer's Association International Conference (AAIC) • GlobeNewswire Inc. • 07/30/2024 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/24/2024 11:15:52 AM
- Vigil Neuroscience Announces Interim Data from its Ongoing Phase 1 Clinical Trial Evaluating VG-3927 in Healthy Volunteers Supporting Continued Development in Alzheimer’s Disease • GlobeNewswire Inc. • 07/24/2024 11:00:00 AM
- Vigil Announces Upcoming Presentations on its Small Molecule TREM2 Agonist VG-3927 at the 2024 Alzheimer's Association International Conference • GlobeNewswire Inc. • 07/18/2024 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/18/2024 11:15:31 AM
- Vigil Neuroscience Provides Update on Clinical Development Strategy to Pursue Potential Accelerated Approval Pathway for Iluzanebart in ALSP • GlobeNewswire Inc. • 07/18/2024 11:00:00 AM
- Vigil Neuroscience Announces $40 Million Strategic Investment from Sanofi • GlobeNewswire Inc. • 06/27/2024 06:00:03 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 09:05:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 09:05:04 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/06/2024 08:05:55 PM
- Vigil Neuroscience to Present in Upcoming June Investor Conferences • GlobeNewswire Inc. • 05/30/2024 11:05:00 AM
- Vigil Neuroscience to Present at The Citizens JMP Life Sciences Conference • GlobeNewswire Inc. • 05/08/2024 11:40:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2024 09:00:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2024 09:00:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2024 09:00:27 PM
FEATURED Nightfood Signs Letter of Intent to Acquire Los Angeles Cooking School, Integrating Automation and Robotics with World-Class Culinary Training • Oct 1, 2024 8:30 AM
FEATURED ZenaTech, Inc. (NASDAQ: ZENA) To Commence Trading Today • Oct 1, 2024 7:00 AM
Integrated Ventures, Inc Reports Total 2024 Revenues Of $5,863,935 vs $3,862,849 for 2023. • INTV • Oct 1, 2024 9:00 AM
Element79 Gold Corp secures loi for launching tailings reprocessing business in Arequipa, Peru • ELMGF • Oct 1, 2024 6:38 AM
BARRON'S COVE to Premier at the Hamptons International Film Festival • APHP • Sep 30, 2024 2:56 PM
Lingerie Fighting Championships Signs Broadcast Deal With Maybacks Global Entertainment • BOTY • Sep 26, 2024 9:00 AM